Lucid Diagnostics Investor Relations Material

Lucid Diagnostics Inc. is a medical diagnostics company focused on the early detection of esophageal precancer and cancer. The company develops and commercializes diagnostic tests that aim to identify patients at risk of esophageal adenocarcinoma, a cancer often associated with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Lucid's lead product, the EsoCheck diagnostic device, is designed to collect esophageal cells in a non-invasive procedure for further analysis using its EsoGuard test, which detects genetic changes associated with cancer risk. The company’s technology provides a less invasive alternative to traditional diagnostic methods like endoscopy. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.